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Abstract
Aims Analyze the relationship between obesity and influenza.
Methods Basal hormone milieu, defective response of both innate and adaptive immune system and sedentariness are major 
determinants in the severity of influenza viral infection in obese patients. Being overweight not only increases the risk of 
infection and of complications for the single obese person, but a large prevalence of obese individuals within the popula-
tion might increase the chance of appearance of more virulent viral strain, prolongs the virus shedding throughout the total 
population and eventually might increase overall mortality rate of an influenza pandemic.
Results Waiting for the development of a vaccination against COVID-19, isolation of positive cases and social distancing 
are the primary interventions. Nonetheless, evidence from previous influenza pandemics suggests the following interven-
tions aimed at improving immune response: (1) lose weight with a mild caloric restriction; (2) include AMPK activators 
and PPAR gamma activators in the drug treatment for obesity associated with diabetes; and (3) practice mild-to-moderate 
physical exercise.
Conclusions Due to prolonged viral shedding, quarantine in obese subjects should likely be longer than normal weight 
individuals.
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Introduction
COVID-19 epidemic is caused by an influenza-like virus 
strain (SARS-CoV-2). Since the “Spanish” influenza pan-
demic of 1918, it is known that malnutrition (both under- 
and over-nutrition) is linked to a worse prognosis of the viral 
infection [1]. The 1957–1960 “Asian” and the 1968 “Hong 
Kong” influenzas confirmed that obesity and diabetes lead 
to a higher mortality as well as a more prolonged duration of 
illness even if the subjects were without other chronic con-
ditions that increase the risk of influenza-related complica-
tions [2, 3]. During the 2009 Influenza A virus (IAV) H1N1 
pandemic, obesity was also linked to increased risk of severe 
disease and a risk factor for hospitalization and death [4].
In industrialized countries, about 50% of the population 
is overweight or obese, with prevalence increasing annually. 
In the USA, the last NHANES report indicated that 34% 
Americans are obese according to WHO criteria [5]. One 
model from the Center for Disease Control and prevention 
(CDC) suggested that between 160 million and 210 mil-
lion Americans could contract the disease over a 12-month 
period. Based on mortality data and current hospital capac-
ity, the number of deaths under the CDC’s scenarios ranged 
from 200,000 to as many as 1.7 million [6].
Herein, we will present some considerations and evi-
dence concerning the impact of the high prevalence of obe-
sity in the diffusion and perpetuation of the epidemics of 
COVID-19.
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Why do obese patients present a worse 
clinical picture than lean subjects?
Obese and obese-diabetic subjects have an alteration at dif-
ferent steps of the innate and adaptive immune response, 
characterized by a state of chronic and low-grade inflam-
mation [7]. This pathway contributes to systemic meta-
bolic dysfunction that is associated with obesity-linked 
disorders.
Firstly, obese subjects have chronically higher leptin 
(a pro-inflammatory adipokine) and lower adiponectin 
(an anti-inflammatory adipokine) concentrations. This 
unfavorable hormone milieu also leads to a dysregulation 
of the immune response and can contribute to the patho-
genesis of obesity-linked complications [8]. In the basal 
state, obese patients have a higher concentration of sev-
eral pro-inflammatory cytokines like alpha-TNF, MCP-1 
and IL-6, mainly produced by visceral and subcutaneous 
adipose tissue leading to a defect in the innate immunity 
[9]. When an antigen is presented, the obesity-related 
chronic inflammation causes a reduced macrophage acti-
vation and a blunted pro-inflammatory cytokine produc-
tion upon macrophage stimulation [10]. The reduced mac-
rophage activation after an antigen is presented explaining 
the poor vaccination success of obese subjects [11]; this 
unique obesogenic microenvironment explains the emer-
gence of antiviral-resistant and vaccine escape variants in 
the obese population [11, 12]. Also B and T cell responses 
are impaired in obese and obese-diabetic patients, and this 
causes an increased susceptibility and a delay of resolution 
of the viral infection.
Zhang et al. proposed that leptin resistance was a co-
factor for the 2009 A (H1N1) pandemic influenza, leptin 
being a major regulator of B cell maturation, development 
and function [13]. Similarly, obese patients may present 
with numerical and functional alterations of lymphocytes 
leading to impaired memory T cell responses and vaccine 
efficacy [14]. Obesity inhibits both virus-specific CD8 + T 
cell responses and antibody responses to the seasonal 
influenza vaccine; again a suboptimal macrophage func-
tionality and maturation characteristic of the obese host 
may contribute to the poor vaccine response [15].
A dysregulated pro-inflammatory response contributes 
to the severe lung lesions observed in victims during the 
influenza pandemic. A robust CD8 + T cell response plays 
an important role in protection against novel influenza 
virus strains and subtypes.
Several studies on IAV infection in OB mice show 
increased disease severity, increased secondary bacterial 
infections and a reduced vaccine efficacy [16]. In fact, 
in obese mice there is a delayed and blunted immune 
response, probably due to a reduced interferon (INF), 
adaptive cellular and antibody-mediated responses. 
Recently, Honce et al. found that serial passaging of a 
human H1N1 influenza virus through diet-induced mod-
els of obesity mice (DIO) or genetically obese mice (OB) 
results in a more virulent disease with an increased viru-
lence and morbidity; in the mouse model, deep-sequencing 
viruses revealed several mutations in obese host-passaged 
viruses and an impairment of the interferon response is 
permissive for the generation of more virulent IAV popu-
lations. These findings are not limited by viral subtype and 
are also found in human studies. Diminished INF response 
and an increased influenza virus replication were found in 
normal bronchial epithelial (NHBE) cells derived from 
obese subjects [16–18].
Another important problem among obese subjects is 
physical inactivity. Sedentariness or reduced physical activ-
ity is characteristic of obese patients with respect to lean 
subjects. Reduced physical activity per se [19] or mediated 
by insulin resistance [20] impairs immune response against 
microbial agents at several steps of the immune response, 
including macrophage activation and inhibition of pro-
inflammatory cytokines.
Both physical activity and exercise are positively associ-
ated with favorable outcomes in metabolic (diabetes, obese 
and metabolic syndrome) and immunological (immune acti-
vation levels, vaccination efficacy and immune senescence) 
health; physical activity interventions have demonstrated the 
potential to reduce the risk of complications by modulating 
inflammation, augmenting the immune system and improv-
ing vaccination outcomes in the elderly [21].
It is also important to consider as a potential cause of the 
worse clinical picture of obese individuals the dynamic of 
pulmonary ventilation in these subjects, with reduced dia-
phragmatic excursions and a relative increase in anatomical 
death space.
Why are obese patients potentially more 
contagious than lean subjects?
Three factors make obese subjects more contagious than 
leans: First, obese subjects with influenza shed the virus 
for a longer period of time (up to 104% longer) than lean 
subjects, potentially increasing the chance to spread the 
virus to others [22]. Secondly, the obese microenvironment 
favors the emergence of novel more virulent virus strains. 
This is due mainly to the reduced and delayed capacity to 
produce interferons by obese individuals and animals [17, 
18]. The delay in producing interferon to contrast viral 
replication allows more viral RNA replication increasing 
the chances of the appearance of novel, more virulent viral 
strains [18]. Thirdly, body mass index correlates positively 
with infectious virus in exhaled breath [23]. This finding was 
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especially significant for males, which leads to the hypoth-
esis that the higher ventilation volumes or a differential chest 
conformation might explain this fact [23].
Can a virus infection induce weight gain?
The relationship between viral infections and obesity is more 
complex than a simple worsening of the influenza infec-
tiveness and clinical picture and outcome in obese patients. 
Adenovirus 36 (Adv36) is the most studied infectious agent 
probably associated to obesity. Adenoviruses are DNA 
viruses causing mainly respiratory infections which were 
indicated both in animal models and in humans to be con-
tributing factors for increased adiposity [24] (Fig. 1). Atkin-
son et al. showed in over 500 individuals and 28 twin pairs 
a correlation between BMI and Adv36 positivity, with 30% 
of positivity in obese vs 11% positivity in lean individuals 
[24]. The proposed mechanisms via which Adv36 infection 
may lead to obesity are several: First, the increase in chronic 
inflammation via rise in MCP-1 (macrophage chemoattract-
ant protein I) which is activated by NF-kB [25]. Second, 
a reduction in leptin expression in the adipocytes leading 
to lipid accumulation by a decrease in lipolysis, a down-
regulation of the adipocyte genes involved in lipid oxidation 
and fatty acid synthesis [26]. Third, the increase in glucose 
uptake in the adipocytes leads to an energy surplus in the 
cells glucose-dependent [27]. Fourth, an up-regulation of 
adipogenesis is due to an improvement in adipocyte prolif-
eration and differentiation [28]. Particularly, PPAR gamma 
genes and other RNA expressions factors related to adipo-
cyte genesis increase.
The effects of influenza virus on infected mammalian 
cells generally result in a metabolic shift toward an increase 
in glycolytic rate and a decrease in ATP production [29]. The 
authors hypothesize that the onset of apoptosis causes this 
metabolic imbalance during the late stage of the influenza 
virus replication process [29]. This pattern resembles an 
insulin-resistant condition with a reduction in the mito-
chondrial pyruvate dehydrogenase complex (PDC) activity, 
usually involved in the rate of carbohydrate oxidation con-
trol. PDC is an important modulator of energy and meta-
bolic homeostasis, and insulin resistance is associated with 
increased skeletal muscle pyruvate dehydrogenase kinase 
(PDK) that phosphorylates and inactivates PDC. Increased 
PDK4 expression in muscle has been observed in insulin-
resistant status, including obesity [14, 30]. In mice infected 
by the H1N1 virus, there is a marked down-regulation of 
PDC activity and ATP level, with selective up-regulation of 
PDK4 in the skeletal muscles, heart, liver and lungs.
Influenza is characterized by cytokine storm and meta-
bolic disorders. In this contest PDC, have an important role 
by catalyzing oxidative decarboxylation of pyruvate and 
linking glycolysis to the tricarboxylic acid cycle (TCA) and 
fatty acid synthesis. In mice, Yamane et al. [31] demonstrate 
that oral administration of dichloroacetate (DADA, a PDK4 
inhibitor) restored PDC activity and ATP level, ameliorated 
metabolism disorders, suppressed cytokine storm, trypsin 
up-regulation and viral replication.
What are the lessons to be learned 
from previous influenza virus infections 
in obesity?
Incubation time for COVID-19 is considered 14 days, at 
most. Based on the concept of prolonged shedding of the 
virus in obese subjects [22], quarantine should be pro-
longed in obese with respect to lean subjects, presumably 
doubled. Until a specific vaccine is not available, the only 
actions that can be taken are isolation of positive patients 
and potentiation of positive immune modulation response. 
Diet and mainly physical exercise as immune modulatory 
action not only aimed at losing weight but also at quickly 
Fig. 1  The figure schematizes 
the bidirectional relationship 
between influenza/influenza-
like viral infections and obesity. 
Adenovirus 36 was linked to the 
development of obesity. Obese 
condition is characterized by 
higher viral charge in breath and 
prolonged virus shedding. Life-
style interventions and drugs 
commonly used to treat diabetes 
associated with obesity, cause a 
positive immune-modulation
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improving immune modulation; morbidity and mortality 
may, in fact, be reduced with regular exercise, even without 
substantial weight loss. Several studies suggest that regular 
physical exercise enhances levels of cytokines production 
mediated via TLR (toll-like receptor) signaling pathways 
during a microbial infection, improving host resistance to 
pathogen invasion [19]. An additional benefit of exercise is 
the enhancement of the antioxidant defense system and the 
oxidative stress reduction.
Warren et al. demonstrate that exercise improved host 
immunity to IAV infection in both obese and non-obese 
mice. Particularly, in obese mice, physical activity reversed 
the obesity-associated impairments in host-immune defense 
[32].
The results suggest that physical activity increased 
immune activation (BAL cytokine, chemokine and cell 
infiltration) early during infection, “restoring” the immune 
response of obese mice to a “normal phenotype”; in fact, 
obesity delayed the immune response, rather than com-
pletely inhibiting it.
Exercise affects energy balance as well as leptin response, 
Type I IFN responsiveness, muscle PDC activation, further-
more increases serum anti-influenza virus-specific IgG2c 
antibody and CD8 + T cell percentage in BAL; all mecha-
nisms may be essential in host protection from infection [30, 
32].
In summary, regular physical exercise emerges as a cor-
nerstone as a preventive measure to improve host defense 
against influenza viral infection and other metabolic diseases 
in obese subjects (but not only). Furthermore, the increase in 
overweight and metabolic syndrome among adolescents in 
US [33, 34] and other industrialized countries [35, 36] con-
stitutes an additional problem. In fact, being social distanc-
ing the only preventive measure that can be taken waiting 
for a vaccine against COVID-19, children and adolescents 
constitute a population where the actuation of social distanc-
ing is more difficult than in adults and where, apparently, 
there is a less symptomatic disease with a higher chance of 
having asymptomatic virus carriers.
Is there an Immunomodulatory therapy 
to prevent influenza?
The strongest, non-pharmacological, positive immunomodu-
latory intervention is physical exercise [37]. Moderate aero-
bic exercise (fit-walking, biking, swimming, jogging) has 
an anti-inflammatory effect decreasing alpha-TNF, MCP-1 
and IL-6 and increasing IL-10 [37]. In addition, physical 
exercise causes an improvement in the hormone milieu 
increasing adiponectin and insulin sensitivity and decreas-
ing insulin and leptin levels, reversing the altered hormone 
milieu of obese patients (Fig. 1). Along this line, Zheng et al. 
showed that regular exercise enhances the immune response 
against microbial antigens in humans [19]. It is interesting to 
note that positive immunomodulation can be achieved only 
with mild-to-moderate intensity exercise. In contrast, high-
intensity or prolonged exercise (like running a marathon) 
is known to deplete the immune response, mainly due to 
the increase in endogenous cortisol [37]. The basic cellular 
mechanism via which physical exercise exerts most of its 
effect is an activation of AMP-kinase [38].
Besides moderate physical exercise, two classes of drugs 
commonly used in obese and/or diabetic patients were 
shown to positively modulate the immune system.
1. AMPK activators. Metformin (MET) is a firstline 
drug for the treatment of type 2 diabetes mellitus and is 
used often off label to treat several forms of obesity-related 
disease (e.g., PCOS). Metformin is a potent stimulator of 
AMPK activation, and as we proved, it reduces sedentari-
ness, increasing the activity in rodents [38]. This study dem-
onstrated that metformin improves mice physical aerobic 
performance, ameliorates myotubes formation and prevents 
oxidative stress damage, modulating ERK and SOD (super-
oxide dismutases) signaling; therefore, we hypothesized that 
MET could also act as an antioxidant agent [37].
Other published results have suggested that MET has 
direct anti-inflammatory effects: For example, MET reduces 
lipopolysaccharide-induced pro-inflammatory responses in 
monocytes and macrophages, down-regulates Th17 cells, 
decreases TNF-α receptor signaling and NF-kB activation 
in endothelial cells and smooth muscle cells.
Diaz et al., in vivo and in vitro, observe a reduced B cell-
intrinsic inflammation and an improved antibody response 
with a consequent increase in the response to the influenza 
vaccine in type 2 diabetes patients taking MET. In conclu-
sion, their results show that MET improves B cell responses 
through reduction in B cell-intrinsic inflammation and 
increased AMPK function, so AMPK may be a therapeutic 
target [39].
2. More specific AMPK (AMP-activated protein kinase) 
activators like AICAR (aminoimidazole carboxamide rib-
onucleotide) are still under study as immune modulators. 
AMPK is an enzyme that exerts anti-inflammatory effect 
upon activation, and it is also recognized as a stimulator of 
PPARs [40, 41]. In a murine model, Zhao et al. demonstrated 
that the administration of AICAR resulted in a decreased 
severity of lung injury and pro-inflammatory processes, as 
determined by diminished neutrophil accumulation and low-
ered levels of TNF-α and IL-6 in bronchoalveolar lavage 
fluid [42].
Moseley et al. reported improved survival in influenza 
virus-infected mice treated with AICAR and a further 
improved survival (by 60%) using combination therapy 
(AICAR + pioglitazone). The authors conclude that the 
results of their study provide preliminary evidence that 
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stimulating the PPAR axis (with AICAR and PPARγ ago-
nists) may prove to be a beneficial effect in the severe influ-
enza infection [41].
3. PPAR gamma activators. Peroxisome proliferator-acti-
vated receptors (PPARs) are key regulators of inflammation 
and lipid metabolism, their activation results specifically 
in a reduction in inflammatory cytokines (as IL6, INF γ) 
[40]. Rosiglitazone and pioglitazone (two PPARγ agonists) 
are insulin-mimetic drugs used in type 2 diabetes with high 
overall potential in reducing influenza virus infection [40]. 
Pioglitazone seems to suppress inflammation by reducing 
MCP-1 expression, an important mediator of host inflam-
mation [40]. Pioglitazone was shown to increase survival of 
infected mice up to 40%, and the benefit may be attributed 
to modulation of subject inflammatory response [40, 41]. 
The combination of pioglitazone and AICAR increase sur-
vival of infected mice from 30 up to 100% [41]. Therefore, 
metformin, AICAR and PPARγ agonists, in combination or 
alone, might be studied and then used in the treatment of 
severe influenza in association with other antiviral/immu-
nomodulatory drugs in the future.
Conclusions
Basal hormone milieu, defective response of both innate 
and adaptive immune system and sedentariness are major 
determinants in the severity of influenza viral infection in 
obese patients. Being obese not only increases the risk of 
infection and of complications for the single obese person, 
but recent evidence indicates that a large obese population 
increases the chance of appearance of more virulent viral 
strain, prolongs the virus shedding throughout the total 
population and eventually may increase overall mortality 
rate of an influenza pandemic. Waiting for the development 
of a vaccination against COVID-19, stated that isolation of 
positive cases and social distancing are the primary interven-
tion, evidence from previous influenza pandemics suggests 
the following for our obese and obese-diabetic patients: 1. 
lose weight with a mild caloric restriction. In addition to 
the obvious positive effect of weight loss, caloric restriction 
activates AMP-kinase, potentiating the immunomodulatory 
effect of physical exercise; 2. include metformin and piogl-
itazone (when not contraindicated) in the drug treatment for 
type 2 diabetes; and 3. practice mild-to-moderate physical 
exercise in order to potentiate positive immunomodulation. 
Finally, present evidence suggests a prolongation of quaran-
tine period in adult and adolescents obese patients.
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